Ozarelix

Summary

Ozarelix is a third-generation GnRH antagonist peptide investigated primarily for the treatment of prostate cancer and benign prostatic hyperplasia (BPH). Unlike GnRH agonists, it produces immediate androgen suppression without an initial hormonal flare, making it potentially advantageous in patients with advanced prostate cancer at risk of clinical exacerbation.

Mechanism of Action

Competitive antagonist of gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, leading to immediate suppression of LH and FSH secretion without an initial testosterone surge (flare), resulting in rapid castrate levels of testosterone.

Routes of Administration

Goals & Uses

• Prostate cancer androgen deprivationOncologyModerate
• Reduction of lower urinary tract symptoms (LUTS)UrologyLow
• Testosterone suppression without flareEndocrinologyModerate
• Benign prostatic hyperplasia (BPH) symptom reliefUrologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to GnRH analoguesAllergy/ImmunologyHigh

Adverse Effects

• QT interval prolongationCardiacUncommon
• Injection site reactionsLocalCommon
• Hot flashesEndocrine / VasomotorCommon
• FatigueGeneralCommonLow energy or tiredness
• Erectile dysfunctionSexual/ReproductiveCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• Anticoagulants (e.g., warfarin)Low
• QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)Moderate

Population Constraints

• Pediatric patientsAgeAbsolute
• Females of reproductive potentialReproductiveRelative
• Patients with osteoporosisMusculoskeletalRelative
• Patients with pre-existing cardiovascular diseaseCardiovascularRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; evaluated in European clinical trials for prostate cancer and BPH.
• United StatesInvestigationalStudied in Phase II clinical trials; no FDA approval obtained. Development appears stalled.
• United KingdomInvestigationalNo MHRA approval; remains an investigational compound.

Ozarelix has not received FDA, EMA, or other major regulatory approval. It was studied in Phase II clinical trials for prostate cancer and BPH but development has not progressed to Phase III or approval as of available data.

Evidence & Sources

No sources recorded yet.